Wands Factors

The Wands factors come from In re Wands (Fed. Cir. 1988), a landmark case defining the multi-factor test for § 112(a) enablement: STATUTORY BASIS: 35 U.S.C. § 112(a) requires the specification to contain a 'written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to make and use the same'; THE UNDUE EXPERIMENTATION STANDARD: a patent specification does not need to enable ZERO experimentation; it must enable a POSITA to practice the invention WITHOUT UNDUE EXPERIMENTATION; the question is whether the amount of experimentation required is UNDUE, considering the circumstances; THE EIGHT WANDS FACTORS: (1) THE QUANTITY OF EXPERIMENTATION NECESSARY: how many experiments must a POSITA run to practice the full scope of the claims?; for a single small molecule, one synthesis might be sufficient; for a broad antibody genus, the number of candidates to test could be enormous; (2) THE AMOUNT OF DIRECTION OR GUIDANCE PRESENTED: does the specification provide detailed protocols, step-by-step instructions, or clear guidance?; the more guidance, the less experimentation is required; (3) THE PRESENCE OR ABSENCE OF WORKING EXAMPLES: actual working examples (experimental data) are strong evidence of enablement; prophetic examples help but carry less weight; no examples at all is a red flag; (4) THE NATURE OF THE INVENTION: a simple mechanical invention requires less enabling disclosure than a complex biological system; the complexity of the invention affects how much guidance the spec must provide; (5) THE STATE OF THE PRIOR ART: if the prior art already provides a roadmap for making the invention, the spec needs to provide less; if the field is nascent with little background knowledge, more detailed disclosure is needed; (6) THE RELATIVE SKILL OF THOSE IN THE ART: a highly skilled POSITA can fill in gaps from their general knowledge; a lower-skill POSITA needs more direction; (7) THE PREDICTABILITY OR UNPREDICTABILITY OF THE ART: PREDICTABLE ARTS (e.g., mechanics, traditional chemistry): routine experimentation can reliably produce expected results; less disclosure needed; UNPREDICTABLE ARTS (e.g., biotechnology, pharmaceutical formulation): small structural changes can produce dramatically different results; much more disclosure and examples needed; (8) THE BREADTH OF THE CLAIMS: the broader the claims, the more the specification must enable across the full claim scope; a claim covering all antibodies that bind a target is much broader than a claim to specific antibody sequences; NO SINGLE FACTOR IS DISPOSITIVE: enablement is evaluated holistically, weighing all eight factors together; some factors may favor enablement (high POSITA skill; predictable art) while others cut the other way (broad claims; few examples); the court or PTAB makes an overall judgment.

Amgen Inc. v. Sanofi (S.Ct. 2023) is the most important recent genus enablement decision and significantly tightened the standard: THE CLAIMS AT ISSUE: Amgen claimed ALL antibodies that (1) bind to a specific region (the sweet spot) on the PCSK9 protein, and (2) block PCSK9 from binding to the LDL receptor; these are defined by FUNCTION (what the antibodies do), not by STRUCTURE (what the antibodies look like chemically); THE DISCLOSURE: Amgen's specification disclosed about 26 specific antibody sequences and a 'roadmap' method for discovering other antibodies in the genus; the specification did NOT disclose the structural features that would predict whether a new candidate antibody would fall within the functional claim scope; THE COURT'S HOLDING: the Supreme Court UNANIMOUSLY held the claims invalid for lack of enablement; the specification enabled POSITA to make only a small fraction of the claimed genus; enabling 26 antibodies does not enable ALL antibodies that perform the claimed function; THE CORE PRINCIPLE FROM AMGEN: 'if a patent claims an entire class of processes, machines, manufactures, or compositions of matter, the patent's specification must enable a person skilled in the art to make and use the entire class'; 'a specification that enables only a small genus does not enable all of the species within that genus'; SKY-IS-THE-LIMIT CLAIMS: the Court criticized 'sky-is-the-limit' genus claims: 'If the claims are to extend to all antibodies that work [in a defined way], then the specification must teach those skilled in the art how to make and use all such antibodies...'; WANDS FACTOR 8 (BREADTH): Amgen illustrates how very broad functional claims create an overwhelming breadth problem under Wands factor 8; WANDS FACTOR 7 (PREDICTABILITY): antibodies are in an UNPREDICTABLE art — small sequence changes can dramatically alter binding; this made the broad genus claim particularly difficult to enable; POST-AMGEN LANDSCAPE: patent practitioners now must be more careful about broad functional antibody and genus claims; specification must include: representative examples across the full claimed scope; structural guidance for discovering other genus members; data demonstrating the claimed function across the breadth; the claim scope must be calibrated to what was actually discovered and enabled.

The predictability of the technology field is one of the most consequential Wands factors: PREDICTABLE ARTS — MINIMAL DISCLOSURE NEEDED: in predictable arts, a POSITA can routinely practice the full claim scope based on limited examples; MECHANICAL INVENTIONS: if a specification shows how to make one embodiment of a gear mechanism, a POSITA typically can make many variations; a claim covering 'a gear mechanism for [purpose]' is likely fully enabled by a single working example; TRADITIONAL CHEMISTRY: for simple organic chemistry, a POSITA can use established synthetic routes; one working example of a synthesis often enables related analogs; ELECTRICAL CIRCUITS: standard circuit designs with well-known component behavior; working examples reliably predict other embodiments; UNPREDICTABLE ARTS — EXTENSIVE DISCLOSURE NEEDED: in unpredictable arts, experimental results cannot be predicted from structure alone; BIOTECHNOLOGY: why biotech is unpredictable: small amino acid changes can eliminate antibody binding; promoter changes can dramatically alter expression levels; cell line variations can affect protein folding; PHARMACEUTICALS: drug activity depends on complex structure-activity relationships; one compound working doesn't predict that a broad class will work; POLYMER SCIENCE: polymer properties depend on polymerization conditions, molecular weight distribution, and copolymer ratios; COMBINATORIAL CHEMISTRY: large virtual libraries of compounds cannot be enabled by testing only a few members if the art is unpredictable; PRACTICAL EXAMPLES OF PREDICTABLE vs. UNPREDICTABLE: PREDICTABLE: 'A device for cutting paper comprising a blade mounted on a base' — a POSITA can make countless variations from one example; UNPREDICTABLE: 'An antibody that inhibits PCSK9 activity' — the specification must provide extensive examples because antibody structure cannot be predicted from the functional description; HYBRID CASES: many modern technologies span predictable and unpredictable sub-areas; applicants may need to provide more examples in the unpredictable sub-area.

The level of enabling disclosure required varies by technology but certain practices consistently satisfy or fail enablement: PRACTICES THAT SUPPORT ENABLEMENT: (1) WORKING EXAMPLES: actual experimental data is the gold standard; results showing the inventor made and tested at least one embodiment of the full claimed scope; (2) SPECIFIC PROTOCOLS: step-by-step instructions that a POSITA could follow to reproduce the invention; especially important in biotech (cell culture conditions; purification protocols; assay conditions); (3) QUANTITATIVE GUIDANCE: specific temperatures, concentrations, times, and other parameters; ranges with acceptable values; (4) DEPOSIT OF BIOLOGICAL MATERIAL: for microorganism and cell line claims, deposit in a recognized depository (ATCC; DSMZ); deposit cures enablement issues for specific biological materials; (5) WORKING EXAMPLES ACROSS CLAIM BREADTH: for genus claims, examples spanning the full claim scope — not just the best embodiment at one end; (6) PRIOR ART REFERENCE INCORPORATION: incorporating prior art that fills in the knowledge POSITA would need; PRACTICES THAT RISK ENABLEMENT REJECTION: (1) PROPHETIC EXAMPLES ONLY: examples written as if performed ('compound X was added') but actually untested; acceptable but riskier than working examples; must be labeled to disclose they are prophetic; (2) SINGLE WORKING EXAMPLE WITH BROAD CLAIMS: one example + broad genus claim = common rejection for unpredictable arts; (3) VAGUE GUIDANCE: 'one of skill in the art will be able to determine the appropriate conditions' — courts find this does not satisfy enablement for complex unpredictable technologies; (4) CLAIMS FAR BROADER THAN EXAMPLES: claiming all compounds that perform a function while having tested only 3-4 specific compounds; (5) MISSING PARAMETERS: crucial processing or synthesis conditions omitted from the specification; DEPOSIT PRACTICE (BUDAPEST TREATY): for microorganisms, plant varieties, and biological materials that are difficult to describe in words, deposit in a recognized depositary institution; deposit under the Budapest Treaty provides international recognition; the deposit must be accessible to the public before the patent issues or before it is needed to satisfy enablement.

Enablement challenges using the Wands factors can be raised in multiple forums with different procedural rules: DISTRICT COURT LITIGATION: BURDEN: accused infringer must prove lack of enablement by CLEAR AND CONVINCING EVIDENCE (i&TRADE v. eBay standard for all invalidity); QUESTION OF LAW: enablement is ultimately a question of law, but it depends on underlying facts about what a POSITA would need to practice the invention; EXPERT TESTIMONY: both parties typically submit expert declarations on Wands factors; expert's POSITA qualifications relevant; MARKMAN HEARING INTEGRATION: while not typically decided at Markman, the court construes the scope of the claims first, which affects how broad the claim scope is for enablement; UNDUE EXPERIMENTATION = FACT QUESTION: whether experimentation is 'undue' given all eight Wands factors is the key fact-intensive question; PTAB — IPR PROCEEDINGS: AVAILABLE GROUND: § 102 and § 103 only in IPR; ENABLEMENT (§ 112(a)) CANNOT BE RAISED IN IPR; this is a significant limitation — an accused infringer in parallel district court litigation may raise enablement there but not at PTAB through IPR; PGR: enablement CAN be raised in PGR (Post-Grant Review) within 9 months of grant; PGR standard: preponderance of evidence (lower than district court's clear and convincing); PROSECUTION CONTEXT: EXAMINER § 112(a) REJECTION: examiner bears the initial burden to provide a factual basis for the rejection; applicant must then show enablement with evidence (declarations; affidavits; experiments); PFAFF v. WELLS ELECTRONICS: the enablement requirement is assessed at the time the patent application was filed; technology developed after filing is generally not available to the applicant to cure an enabling disclosure deficiency; SUPPLEMENTAL EXPERIMENTAL DATA: in some jurisdictions (especially EPO), applicants can submit post-filing experimental data to support enablement for features that were plausibly enabled at the time of filing; the USPTO generally does not allow post-filing data to cure a written description deficiency, but may allow it to demonstrate enablement.